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Abstract
The methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) is associated
with the prognosis in gliomas and in other cancers. Recent studies showed that rs16906252,
an SNP in the MGMT promoter, is associated with promoter methylation and is a predictor of
the overall survival time (OST) and the response to temozolomide (TMZ) treatment. How-
ever, these findings haven’t been systematically investigated in the Han-Chinese population.
We analyzed the relevance between rs16906252 polymorphisms, the MGMT methylation
status, and the OST in 72 Han-Chinese gliomas patients. The MGMT promoter methylation
was measured by bisulfite conversion followed by pyro-sequencing, while rs16906252 was
measured by restriction endonuclease digestion. Contrary to the previous findings, we found
no association between rs16906252 genotypes and promoter methylation on MGMT. The
lower-grade glioma (LGGs) patients carrying the C allele with rs16906252 showed a surpris-
ingly better OST (P = 0.04). Furthermore, the LGG patients carrying hypo-methylated MGMT
promoter and rs16906252 T allele showed significantly poorer prognosis. The prognostic
benefit of MGMT promoter methylation and genotypes on gliomas patients is marginal. A
new molecular stratified patient grouping of LGGs is potentially associated with poorer OST.
Active MGMT might have a protective role in LGG tumors, enabling evolution to severe
malignancy.
Introduction
The annual incidence of gliomas slowly increases and is approximately 5 cases per 100,000
individuals [1]. In humans, gliomas include the glioblastomas and several other types of lower-
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grade gliomas (LGGs). More than 80% of malignant gliomas belong to glioblastomas, with an
average survival time of 14 months [2]. The standard treatment of glioblastomas includes max-
imal surgical resection, and radio- and chemotherapy. Frequently used anti-tumor drugs to
treat glioblastomas include Temozolomide (TMZ) and Bevacizumab [3, 4]. The LGGs
accounts for 15% of total primary brain tumors and approximately 2,000 to 3,000 LGGs are
diagnosed in the United States every year [5, 6].
Promoter methylation of O-6-methylguanine-DNA methyltransferase (MGMT) is an
important clinical predictor to overall survival time (OST) in gliomas and other cancers
including colorectal cancer, lymphoma and lung cancer [7–10]. MGMT protein abundance is
a key indicator of the TMZ treatment response and is routinely assessed by measuring pro-
moter methylation of MGMT [11–13]. Recent studies suggested the rs16906252 genotype in
tumors is associated with MGMT promoter methylation [8, 14, 15]. Compared to the wild type
of homozygous C, glioblastomas that carry the T allele of rs16906252, i.e. heterozygous C and
T or homozygous T alleles, showed hyper-methylated MGMT promoters and a better survival
outcome [16].
The studies supporting the clinical association on the tumoral rs16906252 polymorphisms
and promoter methylation of MGMT are primarily on white patients. Interestingly, the T allele
of the rs16906252 is 6.857% in whites according to the Exome Aggregation Consortium (ExAC)
but is not seen in East Asia [17]. This study aims to investigate the rs16906252 polymorphisms
in Han-Chinese and evaluate the clinical relevance of the rs16906252 genotype, the MGMT pro-
moter methylation in the brain cancer patients.
Materials and methods
Sample collection
The study was approved by the institutional review board (IRB) of the Chang Gung Memorial
Hospital (CGMH). All patients were provided with written informed consent. Seventy-two
patients were recruited between 2005 and 2015 with pathologically confirmed malignant glio-
mas including glioblastomas (WHO grade IV) and LGGs (WHO grade II and III). Tumor tis-
sues were surgically resected, snap frozen in liquid nitrogen, and stored at -80˚C. Matched
control samples were collected from peripheral blood monocytes (PBMCs) during surgery.
Genomic DNA extraction
Tumor DNA were extracted by using the Gentra Puregene kit (QIAGEN) following the manu-
facturer’s protocol. In short, the tumor tissues were lysed with lysis solution using proteinase K
treatment. After protein precipitation by protein precipitation solution and DNA precipitation
by isopropanol, DNAs were washed with 70% ethanol. The pellet was air-dried and re-sus-
pended in Tris-EDTA buffer or deionized water. Blood DNA extraction began with separation
and lysis of lymphocytes from whole blood by using a hypotonic buffer. After PBS wash, lym-
phocytes were treated with lysis solution and proteinase K. DNA were extracted by phenol and
chloroform separation. The same procedure for DNA precipitation and re-suspension was fol-
lowed as that of tumor DNA.
SNP genotyping
The MGMT promoter region was amplified by polymerase chain reaction (PCR) with forward
and reverse primer pairs 5’-GCCCCTAGAACGCTTTGCGTC-3’ and 5’-AGACACTCACC
AAGTCGCAACG-3’ at 65˚C of annealing temperature in a master mix enzyme (New England
Biolabs). Expected length of the PCR amplicons is 74 base pairs (bps) with or without a Hha1
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site depending on the rs16906252 genotypes. The PCR amplicons were treated with the Hha1
enzyme (New England Biolabs), which recognizes the CGCG site presented with the C allele of
rs16906252. The result of Hha1 treatment was then analyzed by electrophoresis on 3% agarose
gel. PCR amplicons with a T variant remained uncut full length (74 bps), while those with the C
allele were fragmented into 48 bps and 26 bps.
Bisulfite conversion and pyrosequencing
To determine promoter methylation, 500 ng tumor DNA were biosulfite-converted, amplified
by the PyroMark MGMT kit (Qiagen) followed by pyrosequencing analysis. Five potentially
methylated sites in the first exon (+17 to +39) of the MGMT gene were analyzed by the EZ
DNA Methylation-GoldTM Kit (Zymo Research) following the manufacturer’s suggestions.
The methylation level was analyzed on the PSQ96 MA system (Qiagen) and quantified by the
Qiagen Pyro-Mark CpG software (Qiagen). Hyper-methylation is defined by the average
Table 1. Summary of the demographic and molecular characteristics of gliomas patients.
Patients %
Age*, mean (range) 48.9 (22–95)
<50 39 54.2 %
50 33 45.8 %
Sex
Male 43 59.7 %
Female 29 40.3 %
Pathology
glioblastomas 34 47.2 %
LGGs 38 52.8 %
Treatment
With TMZ 30 41.7 %
Without TMZ 42 58.3 %
Treatment received
Gross resection 16 22.2 %
Others# 56 77.8 %
At diagnosis
Newly diagnosed 44 61.1 %
Recurrent 28 38.9 %
MGMT methylation
Hyper-methylation 37 51.4 %
Hypo-methylation 35 48.6 %
Tumor rs16906252
CC 51 70.8 %
CT 20 27.8 %
TT 1 1.4%
Germline rs16906252
CC 54 81.8 %
CT 11 16.7 %
TT 1 1.5%
Abbreviations: LGG, lower-grade gliomas.
*Age at diagnosis.
#Others include nearly total, subtotal, and partial resection.
https://doi.org/10.1371/journal.pone.0178842.t001
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methylation sites equal or higher than 10% on the 5 CpG, otherwise regarded as hypo-
methylation.
Statistical analysis
Statistical analyses were performed by the GraphPad prism 5 software. Overall survival time
(OST) was defined as the period from the date of tumor removal to the date of death and was
analyzed by the Kaplan–Meier and Log-rank test for statistical significance. Chi-square analy-
sis was applied to test the association between the methylation status and the rs16906252 geno-
types. P-values of lower than 0.05 were considered significant.
Results
Clinical characteristic of the glioma cohort
Seventy-two glioma patients, including 34 glioblastomas and 38 LGGs, between 2005–2015,
were recruited in this study including 44 newly diagnosed and 28 relapsed patients. The mean
age of all glioma patients was 48.9 years old (22–95 years old) and 59.7% was male. Sixteen
patients received gross total resection, whereas the others received nearly total, subtotal, or
partial removal of tumors (77.8%). Nearly half of the patients (41.7%), mostly the glioblastoma
patients received the TMZ chemotherapy. Forty-four patients passed away with recorded
OSTs, whereas 28 patients were censored due to either being alive at the time of analysis or
loss of contact. Table 1 summarizes the clinical statistics of the patient cohort. The MGMT pro-
moter methylation analysis suggested that slightly more than half (51.4%) of the patients
showed hyper-methylated MGMT promoter. Regarding MGMT genotyping, 29.2% tumors
(21 of 72) carried the T allele at rs16906252, while only 18.2% (12 of 66) carried the same allele
in control DNA. The allele frequency of the rs16906252 minor allele T in tumor samples was
15.3% and 9.8% in the matched-germline control samples. All relevant data of participant-
level is summarized in S1 Table.
rs16906252 genotypes are not associated with promoter methylation in
MGMT
Previous studies suggested that the rs16906252 T allele is associated with methylated promoter
in MGMT in lung [7], colorectal [8, 18], and brain cancer [16]. However, the association is not
replicated in our Han-Chinese gliomas cohort. The MGMT promoter showed an average
methylation of 21.5% and 18.3% in the patients carrying the CC (N = 51) and CT and TT
(N = 21) genotypes, respectively (Fig 1A). When the glioblastomas (Odds Ratio [OR]: 0.7656;
95%Confidence Interval [CI]: 0.5426–1.542; P = 0.7296, S2 Table) and LGG patients (OR:
1.667; 95%CI: 0.3689–7.529; P = 0.5045, S2 Table) were analyzed separately, none of the corre-
lation was significant in either group of patients (Fig 1B and 1C and S2 Table).
rs16906252 predicts OST on LGG patients
The rs16906252 genotypes in tumors are not correlated with OST in glioblastoma patients
(HR: 0.9733; 95%CI: 0.6218–1.559; P = 0.949, S3 Table). The median survival time of patients
with the CC and CT genotypes was 10 months (n = 23) and 9.2 months (n = 11), respectively,
while none of the patients carried the TT genotype (Fig 2A). However, in LGG patients, the
CC genotype is correlated with a longer OST (HR: 0.2902; 95%CI: 0.08898–0.9467; P = 0.0403,
Fig 2B and S3 Table). Patients carrying the CC genotype had a longer median OST (54.6
months; n = 28) compared to those with the CT genotype (24.2 months; n = 10, p = 0.0403).
MGMT promoter methylation and genotyping on glioblastomas and LGGs
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Our results suggest that although not observed in glioblastoma patients, the CC genotype
showed a contradictive longer OST in LGG patients [15].
MGMT promoter methylation is not correlated to OST
Although repeatedly reported as a good predictor, MGMT promoter methylation is not corre-
lated with OST on both glioblastomas and LGG patients in our results (Fig 3). In the glioblas-
toma cohort, the median survival time of methylated and non-methylated patients was 19.3
months (n = 11) and 9.6 months (n = 23), respectively (HR: 0.7617; 95%CI: 0.3436–1.689;
P = 0.5029, Fig 3A and S3 Table). In the LGGs cohort, the median survival time of methylated
and non-methylated patients was 49.2 months (n = 26) and 28.1 months (n = 12), respectively
(HR: 1.031; 95%CI: 0.3572–2.973; P = 0.9555, Fig 3B and S3 Table). Regardless of the methyla-
tion status, circa 40% LGG patients in each group were still alive at the time of analysis. Our
Fig 1. Correlation between the rs16906252 genotype and promoter methylation. MGMT promoter methylation and the rs16906252 genotype
were analyzed for association with (A) all glioma patients (P = 0.5573), (B) glioblastoma patients (P = 0.9899), and (C) LGG patients (P = 0.5827).
Neither all nor subgroups of patients replicated the previously reported association in the Han-Chinese.
https://doi.org/10.1371/journal.pone.0178842.g001
Fig 2. Kaplan-Meier survival analysis of the rs16906252 genotype on (A) glioblastoma patients and (B) LGG patients. (A) Previous
studies suggested that the T allele is associated with a prolonged OST. However, the association is not observed in glioblastoma patients
(P = 0.949). (B) LGG patients with the homozygous C alleles showed a significantly prolonged OST compared to that with CT or homozygous T
alleles (P = 0.0403).
https://doi.org/10.1371/journal.pone.0178842.g002
MGMT promoter methylation and genotyping on glioblastomas and LGGs
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results suggest that promoter methylation is not correlated with OST in Han-Chinese
ethnicity.
rs16906252 genotypes stratify LGG patients with hypo-methylated
MGMT
We further tested the correlation between OST and the combination of methylation and geno-
types with MGMT. The rs16906252 genotypes surprisingly stratify the LGG patients with
hypo-methylated MGMT promoter (Fig 4). The patients with hyper-methylated MGMT and
homozygous C genotype on rs16906252 demonstrated better OST compared with the hetero-
zygous CT genotypes, but this association is not statistically significant (HR: 0.7628; 95%CI:
Fig 3. Kaplan-Meier survival analysis on the extent of MGMT promoter methylation. In glioblastoma patients, most patients (68%) showed
hypo-methylation, but this was opposite in LGG patients (32%). Statistical analysis suggests that the OST is not associated with MGMT
promoter methylation on (A) glioblastoma patients (P = 0.5029) and (B) LGG patients (P = 0.9555).
https://doi.org/10.1371/journal.pone.0178842.g003
Fig 4. OST and the MGMT promoter genotype and methylation on LGGs. The LGG patients were further classified with (A) hyper- and (B)
hypo-methylated promoter in MGMT. The C (or T) allele is not associated with a prolonged OST on patients with methylated promoter (A,
P = 0.7096) but on patients of hypo-methylation (B, P = 0.0252).
https://doi.org/10.1371/journal.pone.0178842.g004
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0.1834–3.173; P = 0.7096; Fig 4A and S3 Table). The patients who had the C allele showed a
prolonged OST while those with the T allele showed significantly shorter OST (HR: 0.1165;
95%CI: 0.01773–0.7657; P = 0.0252; Fig 4B and S3 Table). However, promoter methylation
and genotypes collectively are not correlated with OST on glioblastoma patients with a hypo-
methylated MGMT promoter (S2 Fig).
MGMT promoter methylation and genotypes are not predictors for better
prognosis in the TMZ-treated glioblastoma patients
Previous reports suggested that the glioblastoma patients benefited from TMZ therapy and
demonstrated a prolonged OST. In our cohort, 25 out of 34 (73.5%) glioblastoma patients
were prescribed with TMZ while only five LGG patients were. Of the glioblastoma patients,
TMZ-treated patients showed a marginally prolonged OST (HR: 0.4604; 95%CI: 0.1707–1.242;
P = 0.1256; Fig 5 and S3 Table). The median survival of the TMZ-treated glioblastoma patients
and non-TMZ treated patients differed significantly and are 17.1 months (n = 25) and 7.1
months (n = 9), respectively. Further analysis suggested that rs16906252 genotype is not corre-
lated with OST in TMZ-treated glioblastoma patients (S3A Fig). The patients with hyper-
methylated MGMT promoter showed a marginally prolonged OST (P = 0.1064, S3B Fig), and
the mean OST of the patients with hyper- and hypo-methylated MGMT promoter were 25.7
months and 10 months, respectively. On the other hand, the MGMT promoter genotypes and
methylation were not associated with prolonged OSTs in all glioma patients without TMZ
treatment (S4 and S5B Figs), except the LGGs patients having CC genotypes (S5A Fig).
Discussion
We reported the clinical impact of both promoter methylation and genotypes in MGMT, a
negative regulator of TMZ treatment, to glioma patients [19]. The patients in this study were
all Han-Chinese recruited from a single medical center between 2005 to 2015 to ensure consis-
tent quality of clinical management and patient care. Furthermore, all patients were treated
and cared for by the same neurosurgeon. The drawback of this strategy is the number of ana-
lyzed patients; the findings should be validated in a larger cohort. Furthermore, analysis of iso-
citrate dehydrogenase 1 and 2 (IDH1 and IDH2) and 1p19q shall provide further information
on patient stratification.
TMZ is a commonly used alkylating agent transferring a methyl group to the O6-guanine,
which causes mispairing with thymine during DNA replication and results in apoptosis and
cell death. MGMT removes the methyl group resulting in reduction of the therapeutic effect of
TMZ [20]. The MGMT promoter hyper-methylation has been repeatedly reported as a predic-
tor to effective TMZ treatment in whites and in Han-Chinese, even though some contradictory
results were also reported [21–24]. In our study, only marginal association is seen.
Previous studies suggested that the rs16906252 T allele results in reduced promoter activity
and MGMT expression [7] and is associated with MGMT methylation in glioblastoma [15,
16], colorectal cancer [18, 25, 26], and in a subset of malignant pleural mesothelioma patients
[25]. However, the association is not replicated in our Han-Chinese cohort of glioblastomas
nor in LGG patients. Since SNP often varies among different ethnic groups, statistical differ-
ences might be attributable to ethnic variation. From ExAC and 1000 genome results [17], the
minor allele T is 6.857% and 2% in whites respectively, while it is not present in the East Asian
population. Our results show that the germline MAF (minor allele frequency) is 0.091 in the
Han-Chinese compared to that of 0.1 and 0.14 in the germline genome of the glioma patients
of Western European descent [15, 16]. The MAF in brain cancer patients is only slightly
different.
MGMT promoter methylation and genotyping on glioblastomas and LGGs
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The MAF of rs16906252 in tumors went up to 0.153, while 11 tumors underwent C>T
somatic mutations. The increase of the rs16906252 T allele might drive a potentially evolution-
ary advantage, which presents a poor prognosis in our LGGs result. However, the cellular
influence of the rs16906252 T allele in LGGs remains to be investigated.
Previous studies showed that glioblastoma patients carrying the T allele with hyper-methyl-
ated MGMT promoter had significantly better prognosis [16]. The T allele is not correlated
with a prolonged OST as reported for glioblastoma patients and for the TMZ-treated glioblas-
toma patients [23]. In contrast, the LGGs patients showed a surprisingly prolonged OST when
carrying the rs16906252 C allele while the T allele is in fact associated with a significantly poor
prognosis. While the somatic mutation prevalence in LGGs is higher [27], one explanation is
that active MGMT in LGGs might repair DNA damage and further protect the tumor cells
from apoptosis and cell death. This facilitates the LGGs tumors becoming malignant.
Conclusions
In summary, we showed that glioblastoma patients benefited by receiving TMZ treatment
and confirmed that the glioblastoma patients with hyper-methylated promoter showed a pro-
longed OST although the difference is not statistical significant. Although unable to replicate
some of the previous findings, we present here some novel findings. We identified a positive
correlation between prolonged OST and the rs16906252 CC genotype in LGGs and that the
rs16906252 genotypes predict two distinctive outcomes in the hypo-methylated LGG patients.
Fig 5. Kaplan-Meier survival analysis on the glioblastoma patients with and without TMZ treatment. Among 34
glioblastoma patients, only 9 patients were not treated with TMZ. The patients treated with TMZ showed a prolonged OST
compared to the group without TMZ, although this is not statistically significant (P = 0.1256).
https://doi.org/10.1371/journal.pone.0178842.g005
MGMT promoter methylation and genotyping on glioblastomas and LGGs
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Due to the small number of samples, further validation on a larger cohort of Han-Chinese and
east Asians will shed light on more robust conclusions of the clinical utility or MGMT genetic
testing for brain cancers.
Supporting information
S1 Fig. rs16906252 genotyping byHha1 restriction enzyme digestion and electrophoresis.
Genomic DNA was treated with Hha1 and electrophoresed in a 3% agarose gel. PCR products
(74bp) harboring the rs16906252 T allele prevent Hha1 digestion, while that of the C allele is
fragmented into 48- and 26-bp fragments. The results of patient’s genotype of the homozygous
C, heterozygous CT, homozygous T is illustrated here. U: Undigested; D: Digested.
(TIFF)
S2 Fig. Kaplan-Meier survival analysis on theMGMT genotype and methylation on the
glioblastoma patients. The glioblastoma patients were grouped by their methylation and
genotype of the MGMT promoter. None of the patient groups showed significantly prolonged
OST (P = 0.7358).
(TIFF)
S3 Fig. OST of 25 TMZ-treated glioblastoma patients. (A) The CC or CT genotypes did not
differentiate patients for prolonged OST (P = 0.5319). (B) The patients with the hyper-methyl-
ated MGMT promoter showed better survival outcome (median survival time are 17.1 months
versus 7.1 months) even though statistically insignificant. (P = 0.1064).
(TIFF)
S4 Fig. OST of nine non-TMZ treated GBM patients. (A) These patients had either homozy-
gous C (n = 6) or heterozygous CT genotype (n = 3). However, all showed very short OST
except one patient with CC was still alive at the time of analysis. The genotypes do not differen-
tiate OST (P = 0.3668). (B) The promoter methylation does not differentiate OST, except one
patient with hypo-methylation showed a prolonged OST (P = 0.3198).
(TIFF)
S5 Fig. OST of 33 non-TMZ treated LGG patients. Most LGG patients didn’t receive TMZ
treatment except five patients. The result of the genotype (A, P = 0.0435) and the promoter
methylation (B, P = 0.9745) on 33 non-TMZ treated patients is similar to that of all LGGs
patients.
(TIFF)
S1 Table. Patient clinical information.
(XLSX)
S2 Table. Statistical analysis of the genotypes and the promoter methylation status of the
glioma patients.
(XLSX)
S3 Table. Log-rank test of OST in glioblastoma and the LGG patients.
(XLSX)
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